BEIJING, April 16, 2014 /PRNewswire/ -- Sinovac
Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical
products in China that focuses on
the research, development, manufacturing and commercialization of
vaccines, announced today that it has filed its 2013 Annual Report
on Form 20-F with the U.S. Securities and Exchange Commission for
the year ended December 31, 2013 on
April 16, 2014. The Annual
Report on Form 20-F is now available on the Company's website under
SEC Filing in the Investor Relations section.
The Company will provide a hard copy of its complete audited
financial statements to its shareholders upon request, free of
charge. Requests for a hard copy of the 2013 Annual Report
can be made through the Contact IR page in the Investor Relations
section of the Company's website by submitting complete mailing
details on the request form.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing and
commercialization of vaccines that protect against human infectious
diseases including hepatitis A and B, seasonal influenza, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu) and
mumps, as well as animal rabies vaccine for canines. The Company
recently concluded the phase III clinical trial for enterovirus 71
(against hand, foot and mouth disease) and filed new drug
application with China Food & Drug Administration. In 2009,
Sinovac was the first company worldwide to receive approval for its
H1N1 influenza vaccine, Panflu.1, and has manufactured it for the
Chinese Central Government, pursuant to the government-stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government-stockpiling program. Sinovac is
developing a number of new pipeline vaccines including vaccines for
pneumococcal polysaccharides, pneumococcal conjugate, varicella and
rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the
Philippines. Sinovac has also been granted a license to
commercialize seasonal flu vaccine in Mexico.
Safe Harbor Statement
This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar statements. Among
other things, the business outlook and quotations from management
in this press release contain forward-looking statements.
Statements that are not historical facts, including statements
about Sinovac's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and
uncertainties. A number of important factors could cause actual
results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any
obligation to update any forward-looking statement, except as
required under applicable law.
Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659/9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com
Media:
Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028
Email: aestrada@theruthgroup.com
SOURCE Sinovac Biotech Ltd.